Pn MAPS30plus

2 trials

Sponsors

GlaxoSmithKline Biologicals SA

Conditions

PaediatricsPneumococcal Disease Paediatrics

Phase 1

A trial to evaluate the safety and reactogenicity of an investigational pneumococcal vaccine in infants receiving 3-dose primary dosing series followed by a booster dose at 12 to 15 months of age

Active, not recruitingPACTR202605824103374

GlaxoSmithKline Biologicals SAPaediatrics

Start: 2026-07-10Target: 60Updated: 2026-06-22

A trial to evaluate the safety and reactogenicity of an investigational pneumococcal vaccine in toddlers 12 to 15 months of age receiving a single booster dose

Active, not recruitingPACTR202605631649775

GlaxoSmithKline Biologicals SAPneumococcal Disease Paediatrics

Start: 2026-05-15Target: 45Updated: 2026-06-22